2019
MA25.02 Arrangement and Architecture of Tumor-Infiltrating Lymphocyte on H&E Slides Predict OS in Nivolumab Treated Non-Small Cell Lung Cancer
Wang X, Barrera C, Bera K, Lu C, Feldman M, Schalper K, Rimm D, Velcheti V, Madabhushi A. MA25.02 Arrangement and Architecture of Tumor-Infiltrating Lymphocyte on H&E Slides Predict OS in Nivolumab Treated Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2019, 14: s350-s351. DOI: 10.1016/j.jtho.2019.08.710.Peer-Reviewed Original ResearchNon-small cell lung cancerTumor-Infiltrating LymphocytesCell lung cancerLung cancerLymphocytesCancer
2017
PUB024 Clusters Spatial Arrangement of Tumor Infiltrating Lymphocyte and Cancer Nuclei Predicts Recurrence in Early Stage Non-Small Cell Lung Cancer
Wang X, Corredor G, Romero E, Schalper K, Yang M, Rimm D, Velcheti V, Madabhushi A. PUB024 Clusters Spatial Arrangement of Tumor Infiltrating Lymphocyte and Cancer Nuclei Predicts Recurrence in Early Stage Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2017, 12: s2372-s2373. DOI: 10.1016/j.jtho.2017.09.1887.Peer-Reviewed Original ResearchTetrahydrouridine-decitabine for non-cytotoxic epigenetic therapy of NSCLC to enhance immunotherapeutic effect of anti-PD1 in vivo.
Kang K, Schrump D, Thomas A, Schalper K, Saunthararajah Y, Velcheti V. Tetrahydrouridine-decitabine for non-cytotoxic epigenetic therapy of NSCLC to enhance immunotherapeutic effect of anti-PD1 in vivo. Journal Of Clinical Oncology 2017, 35: 11552-11552. DOI: 10.1200/jco.2017.35.15_suppl.11552.Peer-Reviewed Original ResearchT cellsC57/BL6 miceAbsolute lymphocyte countAnti-PD1 therapyRegulatory T cellsTumor-Infiltrating LymphocytesImmune memory effectTumor-bearing miceDNMT1 depletionMost NSCLCNSCLC responsePharmacologic rationaleG-MDSCSolid cancer tissuesImmunotherapeutic effectsLymphocyte countMedian survivalIFNγ expressionInfiltrating lymphocytesSurvival improvementMAGE-A3BL6 miceLung invasionAntigen presentationMAGE-A1